Comparison between intravenous recombinant human erythropoietin and subcutaneous injection in Thai hemodialysis patients

Journal of the Medical Association of Thailand

Volumn 87, Issue 9, 2004, Pages 1041-1047

  Trakarnvanich, Thananda ^a   Thitiarcharkul, Supachai ^b  

^a NAVAMINDRADHIRAJ UNIVERSITY   (Thailand)

^b THAMMASAT UNIVERSITY   (Thailand)

Author keywords

Erythropoietin; Hematocrit; Hemodialysis patient; Route administration

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; ARTICLE; FEMALE; HEMATOCRIT; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; SIDE EFFECT; THAILAND; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

ADULT; AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; ERYTHROPOIETIN; FEMALE; HEMATOCRIT; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; THAILAND;

EID: 5444225826     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Hynes D, Stroupe K, Greer J, Reda D, Frankenfield D, Kaufman J, Handerson W, Owen W, Rocco M, Wish J, Kang J, Feussner J. Potential cost savings of erythropoietin administration in end stage renal disease. Am J Med 2002; 112: 169-75.
2. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Am J kidney Dis 2002; 35(suppl 1): S182-238.
3. NKF-DOQI Clinical Practice Guidelines for Vascular Access. Am J Kidney Dis 2001; 37(suppl 1): S137-81.
4. European Best Practice Guidelines for the Management of Anemia in Patients with Chronic Renal Failure. Nephrol Dial Transplant 1999; 14 (suppl 5): 1-50.
5. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian J, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P. Pure red cell aplasia and anti erythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346: 469-75.
6. Casadevall N. Antibodies against rHUEPO: Native and recombinant. Nephrol Dial Transplant 2002; 17 (Suppl 5): 42-7.
7. Bunn F. Drug-induced autoimmune red cell aplasia. N Eng J Med 2002; 346: 522 Slb.
8. Eckardt K, Casadevall N. Pure red cell aplasia due to anti-erythropoietin antibodies. Nephrol Dial Transplant 2003; 18: 865-9.
9. Besarab A, Reyes C, Hornberger J. Meta-analysis of subcutaneous versus intravenous epoietin in maintenance treatment of anemia in hemodialysis patients. Am J kidney Dis 2002; 40: 439-46.
10. Boran M, Dalva I, Yazicioglu A, Cetin S. Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients. Nephrol 1993; 63: 113-4.
11. Paganini E, Eschbach J, Lazarus M, Van Stone J, Gimenez L, Graber S, Egrie J, Okamoto D, Goodkin D. Intravenous versus subcutaneous dosing of epoietin alfa in hemodialysis patients Am J Kidney 1995; 26: 331-40.
12. Schoenmakere G, Lamiere N, Dhondt A, Van Loo A, Goten J, Duym P, Vanholder R. The haematopoietic effect of recombinant human erythropoietin in hemodialysis is independent of the mode of administration. Nephrol Dial Transplant 1998; 13: 1770-5.
13. Jensen, Madsen J, Jensen L. Comparison of dose requirement, serum erythropoietin and blood pressure following intravenous and subcutaneous erythropoietin treatment in dialysis patients. Eur J Clin Pharm 1996; 50: 171-7.
14. Castellig, Famalaro A, Semico C. Detection of antierythropoietin antibodies in hemodialysis patients treated with recombinant human erythropoietin. Pharm Res 2000; 41: 313-8.
15. Weber G, Gross J, Kromminga A, Loew H, Eckardt K. Allergic skin and systemic reactions in a patients with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoietin. J Am Soc Nephol 2002; 13: 2381-3.
16. Praditpornsilpa K, Avihingsanon Y, Buranaosot S, Bhokaisuwan N, Kansanabuch T, Eiam-Ong S, Chusil S, Tungsaga K. Recovery of anti-Recombinant-Human-Erythropoietin associated pure red cell aplasia in end stage renal disease patients after renal transplantation. Am J Transplant 2004(suppl 8); 4: 483 (abstract).